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The incidence of oropharyngeal cancers has increased in the western world and Human Papilloma Virus (HPV) has been
recognised as a risk factor in the last decades. During the same period the prevalence of HPV in oropharyngeal tumours has
increased and HPV has been suggested responsible for the increase. The HPV-positive tumours are today recognized as a distinct
subset of head and neck cancers with its own clinopathological and risk proﬁle and have a signiﬁcantly improved prognosis
regardless of treatment strategy. This review summarizes current knowledge regarding human papillomavirus biology, oncogenic
mechanisms,risk factors, and impact of treatment.
1.Introduction
Head and neck squamous cell carcinoma is the sixth most
common cancer worldwide [1]. The incidence of head neck
cancers varies widely around the world and even within
populations. Oral and oropharyngeal cancer constitutes 3–
5% of the malignancies in Europe, while this ﬁgure in parts
of Southeast Asia and India reaches up to 40–50% [2–4].
Eighty to ninety percent of head and neck cancer cases are
considered to be associated with known risk factors, such as
smoking, betel nut chewing, and alcohol abuse [4, 5].
The prognosis for HNSCC is generally low in the more
advanced stages and there has been only a modest improve-
ment in recent years and the treatment frequently sentences
the patient to life-long sequelaes such as diﬃculties with
swallowing, dryness of the mouth, esophageal strictures, and
osteoradionecrosis. Head and neck canceris a heterogeneous
group that diﬀers greatly in tumour aggressiveness and
response to treatment. The treatment is today based on
tumour stage which thus leads to suboptimal outcome for
some patients. The identiﬁcation of predictive markers is
urgent to enable optimization of treatment and reduction of
sequalae for the individual patient.
Despite a decreasing incidence of head and neck squa-
mous cell carcinoma in general, attributed to a decrease in
the prevalence of smoking [6], the incidence of oropharyn-
geal SCC is rising [7–12]. Human papillomavirus (HPV) has
for some time been suggested to be involved in the carcino-
genesis of oropharyngeal cancer. The Agency for Research
on Cancer (IARC) now recognizes HPV as a risk factor
for oropharyngeal cancer, and accumulating molecular and
epidemiological data now show that high-risk types of HPV
are responsible for a subset of oropahryngeal cancer [13–
15]. HPV-positive cancers cases are now in majority in the
western world and these tumours are also shown to have
better outcome than the HPV-negative patients. However,
the natural history and the tumour development biology
of HPV-infection in head and neck tumours are not yet
fully understood and the best management needs further
investigation and clinical trials in order to achieve the best
clinicaloutcomeforthepatientswith HPV-positiveheadand
neck tumours.
2.Human PapillomaVirus(HPV)and
TumourBiology
HPV was ﬁrst identiﬁed in 1949 [16] and today over 100
diﬀerent HPV types have been characterized [17]. HPVs are
small, circular double stranded DNA viruses with a genome
that consists approximately 8000 base pairs. HPV infection2 Journal of Oncology
is highly restricted to basal cells in the mucosal or epithelial
layers. Replication occurs within the nucleus of the infected
cell and is dependent on S-phase entry since it requires
the DNA machinery [18]. The HPV subtypes are divided
into high-risk and low-risk HPV regarding their malignant
potential. Approximately 15 high-risk subtypes are known
but only HPV subtypes 16, 18, 31, 33, and 35 have been
identiﬁedplayingaroleinthedevelopmentoforopharyngeal
head and neck cancer. HPV 16 is the far most common type
detected in oropharyngeal cancer accounting for 90–95% of
the HPV positive tumours [19].
High-risk HPVs produce 2 oncoproteins, E6 and E7,
which are necessary for viral replication through their prolif-
eration stimulating activity and play a key role in malignant
transformation and maintenance. The E6 oncoprotein binds
and induces the degradation of the p53 tumour suppressor
protein via an ubiqutin-mediated process disrupting the p53
pathway which leads to uncontrolled cell cycle progression
[20, 21]. The HPV E7 protein binds and degrades the
retinoblastoma protein (pRb), preventing it from inhibiting
the transcription factor E2F resulting in loss of cell cycle
control. Furthermore, the functional inactivation of Rb
results in upregulation of the p16-protein. P16 is encoded
by the CDKN2A tumour suppressor gene and regulates the
activity of CyklinD-CDK4/6 complexes that phosphorylate
Rb leading to release of the transcription factor E2F which
initiates cell cycle progression. The bound Rb-E2F protein
acts as a negative regulator by inhibiting transcription
CDKN2A,and therefore the functional inactivation of Rb by
E7 thereby the transcriptional inhibition of the p16 gene is
lost. HPV-positive tumours are consequently characterised
by high expression of high levelsof p16 [22]. p16 proteincan
be detected by technically simple immunohistochemistry,
and since several studies have shown a very high correlation
(>90%) to HPV-positively in oropharyngeal tumours, it has
beensuggestedasaclinicallyusefulsorrogatemarker[23,24].
In head and neck cancer caused by the traditional risk
factors, tobacco and alcohol, p53 is commonly mutated
[25, 26] and 9p21-22 is lost early in carcinogenesis resulting
in the loss of the tumour suppressing gene p16 [27].
In contrast, HPV-positive head and neck tumours have
decreasedexpressionofwild-typep53duetotheinactivation
and degradation by the E6 oncoprotein. Furthermore, in a
study by Westra et al. in 2008 [28]i tw a ss h o w nt h a tH P V1 6
and mutated 53 may coexist in a subset of head and neck
squamous cell carcinoma but HPV 16 and disruptive p53
mutations seemed to be nonoverlapping events. An inverse
relationship between HPV-16 infection and disrupted p53
gene mutations in head and neck carcinomas was suggested,
and thus HPV positive head and neck tumours represent
a distinct molecular phenotype with a unique mechanism
of tumorigenesis independent of the mutagenic eﬀect of
tobacco and alcohol.
3.RiskFactorsforHPV
In contrast to the HPV-negative cancers in the head neck
region the vast majority of HPV-positive cancers lack
association with the traditional risk factors, tobacco and
alcohol [29]. Epidemiological studies on HPV-associated
cervical cancer have clearly demonstrated that HPVs are
transmitted by sexual contact [30]a n dt o d a yt h e r ea r e
several studies suggesting that also HPV-positive head and
neck tumours are sexually transmitted. It is assumed that
HPV infection precedes the development of HPV positive
head and neck cancers, and the presence of high-risk HPV
infection on the oral mucosa and seropositivity increase the
riskofdevelopmentofheadandneckcancers[13,14,31,32].
Therefore risk factors for HPV oral infection are likely to be
risk factors for HPV-positve head neck tumours. Oral HPV
infections are rare in newborns of HPV-infected mothers
and in children prior to sexual activity; infections increase
after onset of sexual activity. In addition, an increased risk
for tonsillar cancer among women with cervical lesions
and a higher rate of tonsillar and tongue cancers among
husbands of women with cervical dysplasia or cancer have
been identiﬁed [33]. The risk of HPV-positive head and
neck tumours has been associated with sexual behaviour
including increasing numbers of both vaginal and oral sex
partners, young age at ﬁrst intercourse, and history of
genital warts [34–37]. Also other life style factors like poor
oral hygiene and marijuana use have been discussed and
the most recent report found that the risk of developing
an HPV-16 positive head and neck cancer increased with
increased marijuana use but no correlation to oral hygiene
was found [37]. Whether tobacco and alcohol increase the
risk is not clear where some studies found no association
to development of HPV-positive head neck cancers [13, 37]
while others have found that thier use increase the risk
[38]. Patients with the Fanconi anaemia have increased
risk of HPV-mediated tumourigenesis [13]a n ds o m ed a t a
indicate that HIV-patients have increased rates of HPV-
relateddiseaseintheoralcavitydespiteantiretroviral therapy
[39, 40].
4.Epidemiology
As for other head and neck cancers, the incidence of
orophayrngeal cancer rates varies widely around the world
and even within population signiﬁcant diﬀerences have
been observed. The black population in the United States,
for instance, tends to have higher incidence rates than
whites and hispanic populations all over the country. The
SEER, Surveillance Epidemiology and End Results, covers
approximately 14% of the US population and the age-
standardized rates of tonsillar cancer in whites were 1.4 for
men and 0.4 for women in 1993–1997. For blacks the rates
were 2.9 and 0.6, per 100000 person-years, respectively.
By contrast, in China, the rates of tonsillar cancer are
generally low, for instance, in Beijing where the rates were
0.1 for men and 0.0 for women, respectively. Interestingly,
in Hong Kong and in Taiwan, places with great western
i n ﬂ u e n c e ,t h er a t e sw e r e6t o1 2t i m e sh i g h e rt h a ni nB e i j i n g .
In India, with high rates of oral cancer, the rates of tonsillar
cancer were between 0.8 and 2.8 in men and 0.2 and 0.5 in
women, respectively.Journal of Oncology 3
In most countries the rates tend to be higher in males
than in females with a ratio from 2:1 to 5:1. However, in
the Philippines and in Vietnam women had higher incidence
rates than men. Interestingly, this was true also for the
Philippine population in California.
Also in Europe, the incidence rates show great variations
with intranational variability in some countries. The highest
rates were seen in parts of France, in Somme, where the rates
were as high as 6.4 for men and 0.8 for women [41].
In several western countries, the incidence oforopharyn-
geal cancer has increased greatly in the last decades[7–9, 42–
44]andtheincidencehasincreased mostinmen.Atthesame
time, the prevalence of HPV in those tumours has increased
in a similar way indicating that HPV in fact is responsible for
this increase [11, 42, 45]. HPV has been found in 45–95% of
the oropharyngeal tumours [11, 42, 46] and the prevalence
of HPV 16 has been quite homogenous around the world
[47] in contrast to cervical cancer, where the prevalence of
diﬀerent types of HPV varies around the world [48].
5.HPV inHead-NeckCancers
Apart from having a diﬀerent epidemiology and aetiol-
ogy, the HPV-positive oropharyngeal cancers also consti-
tute a distinct subgroup clinopathologically. HPV-positive
tumours are usually poorly diﬀerentiated and nonkeratiniz-
ing and have a basaloid appearance in contrast to the HPV-
negative that is more moderately diﬀerentiated and kera-
tinizing [49, 50]. HPV-positive tumours also demonstrate
signiﬁcantly lowerlevelsofchromosomal mutationsthan the
HPV-negative tumours [51, 52]. Furthermore, patients with
HPV-positive oropharyngeal cancers in general, especially
tonsillar cancers, tend to be younger at time of diagnosis
[42, 53], possibly with the exception of base of tongue
cancers where no age diﬀerence could be found between the
HPV-positive and HPV-negative cancer patients [10]. The
majority of the patients have no prior history of tobacco
and/orhigh alcohol consumption and havegenerally a better
performance status compared to the HPV-negative patients
[37, 54]. Moreover, HPV-postive tumours often present at a
higher stage with a small T-size (T1-T2) [55] but frequently
there is a large, often cystic, nodal involvement (N+) [56,
57], thus the HPV-positive tumours are often diagnosed in
clinical advanced stages, that is, Stages III-IV [15].
6.ClinicalImplications/EffectonPrognosis
The prognosis for HPV-positive oropharyngeal cancer
patients is better than that for patients with HPV negative
tumours independent of nodal status, age, stage, tumour
diﬀerentiation, or gender [1, 15, 58–60]. Several studies have
shown 80–95% 2-3 years overall survival rate for the HPV-
positive patients compared to 57–62% for the HPV-negative
subgroup of oropharyngeal tumours [60–62].
While it is still unclear whether tobacco is a risk factor
for HPV-induced oropharyngeal tumors, it seems clear that
smoking has a negative impact on relapse and survival for
the HPV-positive tumours [63]. The risk of death and cancer
relapse signiﬁcantly increased by1%foreach additionalpack
year of tobacco smoking [61], indicating that the biological
behaviour of an HPV-positive tumour may be altered by
tobacco use.
Treatment of head and neck tumours today is often
standardized and based on tumour stage despite the knowl-
edge of the heterogeneity regarding tumour aggressiveness
and response to treatment of the tumours varies greatly.
Treatment of patients with advanced disease often includes
both oncological and surgical treatment as both carry acute
side eﬀects and lifelong sequelae. The surgical trend in the
last years, especially regarding neck dissection, has turned
from a veryradical operationtowards more organ preserving
selective/modiﬁed neck dissections when possible, reducing
the morbidity. In contrast, the oncological treatment has
turned in the opposite direction including the develop-
ment of altered fractionation radiotherapy, integration of
chemotherapy with radiotherapy, incorporationofintensity-
modulated radiotherapy, and the introduction of targeted
biological therapy. The combined modality treatment and
the altered/intensiﬁed fractionation have improved outcome
for head neck cancer patients in general [64, 65], but the
morbidity has also signiﬁcantly increased [66–68]. How-
ever, today there is no absolute consensus about patient
selection for altered fractionation regimens, type of chemo-
radiotherapy association, radiation, or chemotherapy dose
schedule. Among older patients with advanced disease, age
over 70 years, the compliance to treatment is low due to
signiﬁcantcomorbidityandpoorperformance [68];thusthis
intense therapy is probably not suitable for this group of
patients.
Patients with HPV-positive tumours in the oropharynx
show an improved survival regardless of treatment strategy.
SuperioroutcomeforHPV-positivetumourshasbeenshown
for surgery [69], convectional and modiﬁed fractionated
radiotherapy[55],inductionchemotherapy[60],concurrent
chemotherapy [61] and induction chemotherapy plus con-
current chemotherapy [60]. Thus, regarding patients with
HPV-positive tumours in oropharynx the debate today is
whether the intense therapy is too aggressive in this group
of patients since they show a superior survival regardless of
treatment strategies.
Strengthening this theory, a recent published study by
Ang et al. [61]s h o w e dn os i g n i ﬁ c a n td i ﬀerence in overall
survival between a concomitant boost accelerated fraction
regimen of radiotherapy and a standard fractionation regi-
men when combinedwithconcurrenthigh-dose cisplatinfor
HPV-positive patients.
The reason for the better response to treatment for
patients with HPV positive tumours is not known. There
are studies that have found an inverse relationship between
tumour HPV status and presence of p53 mutations in
head and neck cancer [50, 70]. The improved response
to oncological treatment observed for patients with HPV-
positive tumours could therefore be explained by the pres-
ence of an intact p53-mediated apoptotic response in HPV-
positive tumours. Another possibility is immunological
factors related to HPV infection [71].4 Journal of Oncology
Today, there is a subgroup of the HPV-positive oropha-
ryngeal cancers that have worse clinical outcome, that do
not respond as well to given treatment, and have a higher
rate of relapses and worse survival than the majority of the
tumours in this group. A question for the future is how to
separate the HPV-positive oropharyngeal tumours in this
relative small group. Several potential clinical markers have
been suggested, p16 [23, 24, 55, 72], Cyklin D1, [73], EGFR
[74–76], p53 [28], and p21 [73], and maybe a combination
of these and other not yet known markers may provide
additionalprognosticinformationandthusguideustoselect
the right patients for the right combination of treatment.
Based on the profound impact of HPV on the response
totreatment forpatientswith oropharyngeal tumours, HPV-
status should be included to standard pathological reporting
in clinic and the planning of treatment strategies for this
group of patients. Future clinical trials comprising patients
with oropharyngeal tumours should include HPV status as
a stratiﬁcation factor in order to identify the least morbid
treatment to cure this group of patients.
7.ConcludingRemarks
HPV-positive oropharyngeal cancer is recognized as a dis-
tinct subset of head and neck squamous cell carcinoma with
a favourable outcome. HPV status is a profound prognostic
factor for overall and progression-free survival, treatment
response,andtumourcontrol.Thesuperioroutcomeisinde-
pendentofnodalstatus,age,stage,tumourdiﬀerentiation,or
gender and regardless of treatment strategy. The explanation
for this diﬀerence is not clearly understood today and is
probably a combination of several factors, patient-related
(younger age, less exposed to tobacco and alcohol, less co
morbidity, etc.) as well as tumour-related factors (presence
of p53-mediated apoptosis).
HPV-positive oropharyngeal tumours represent a dis-
tinct clinopathological proﬁle where there still exist many
questionsto be answered regarding tumourbiologyand how
the disease develops(tumouregenesis).
In future, clinical trials on oropharyngeal tumours need
to take HPV-status in consideration. There is a possibility
that less intense treatment strategies with lower rate of acute
and long-term side eﬀects do not compromise the survival
outcome for this group of patients. Since patients with
HPV-positive oropharyngeal cancers often are younger and
in good health, few severe life-long complications are very
important considerations. We need further knowledge about
the tumour biology and identiﬁcation of additional clinical
useful markers to combine with HPV-status for appropriate
risk stratiﬁcation in future clinical trials in order to optimize
the treatment for each individual patient in the future.
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